Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 21, 2025
Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative StudyElif Car, Liese Barbier, Ingrid Schwarzenberger, et al.
The Journal of Arthroplasty|October 11, 2002
Acute renal failure after local gentamicin treatment in an infected total knee arthroplastyTom M van Raaij, Loes E Visser, Arnold G Vulto, et al.
Clinical Pharmacokinetics|September 24, 2005
Population pharmacokinetics of mycophenolic acid in renal transplant recipientsReinier M van Hest, Teun van Gelder, Arnold G Vulto, et al.
Frontiers in Pharmacology|January 24, 2022
Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory CareYannick Vandenplas, Liese Barbier, Steven Simoens, et al.
Clinical Pharmacology and Therapeutics|April 3, 2020
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic ReviewLiese Barbier, Hans C Ebbers, Paul Declerck, et al.
Frontiers in Pharmacology|July 23, 2016
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal AntibodiesEvelien Moorkens, Clara Jonker-Exler, Isabelle Huys, et al.
BMC Health Services Research|September 29, 2022
Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative studyYannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pediatric Nephrology (Berlin, Germany)|September 1, 2005
Estimation of the glomerular filtration rate in children: which algorithm should be used?Lyonne K van Rossum, Ron A A Mathot, Karlien Cransberg, et al.
Psychopharmacology|September 1, 2005
Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?Tom K Birkenhäger, Walter W van den Broek, Peter Moleman, et al.
Therapeutic Drug Monitoring|January 19, 2006
Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of viewReinier M van Hest, Ron A Mathot, Arnold G Vulto, et al.
Pageof 12